MedPage Today on MSN18h
FDA Expands Guselkumab Approval to Crohn's Disease
The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...
Healio23h
Tremfya’s FDA win as fully subcutaneous option for Crohn’s may pave way to eclipse Stelara
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
Managed Healthcare Executive20h
FDA Approves Tremyfa to Treat Active Crohn’s Disease
Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...
PharmExec19h
FDA Approves Johnson & Johnson’s Tremfya for Crohn Disease
Tremfya is the first and only IL-23 inhibitor with both subcutaneous and intravenous induction options for adults with moderately to severely active Crohn disease in the United States.
EquityBulls9h
Godrej Properties to develop project in Yelahanka, Bengaluru with an estimated revenue potential of ~INR 2,500 crore
Godrej Properties Ltd has purchased ~10 acres of land in Yelahanka, Bengaluru to develop ~1.5 million square feet of saleable ...
EquityBulls9h
IndoStar Capital Finance Ltd receives RBI nod for stake sale in Niwas Housing Finance Pvt Ltd
The Reserve Bank of India has accorded its approval on March 21, 2025 for acquisition of shareholding of up to 100% of the ...